Related Experiment Videos
Prednisone treatment in newly diagnosed type I diabetic children: 1-yr follow-up
Insights
Prednisone treatment in children with type 1 diabetes mellitus did not improve insulin needs or remission rates compared to standard care. Early C-peptide levels were higher in the prednisone group, but this did not translate to better long-term outcomes.
Area of Science:
- Pediatric Endocrinology
- Immunology
- Metabolic Disorders
Background:
- Type 1 diabetes mellitus (T1DM) is an autoimmune disease characterized by pancreatic beta-cell destruction.
- Early intervention strategies aim to preserve residual beta-cell function and improve glycemic control.
- The role of short-term immunosuppression in T1DM management remains an area of investigation.
Purpose of the Study:
- To evaluate the efficacy of short-term oral prednisone treatment in children with newly diagnosed type 1 diabetes mellitus.
- To assess the impact of prednisone on insulin requirements, glycemic control, and beta-cell function (C-peptide levels).
- To determine if prednisone influences the rate of partial remission in pediatric T1DM patients.
Main Methods:
- A randomized controlled trial involving 31 children with new-onset T1DM.
- Group 1 received oral prednisone (60 mg/m²/day for 14 days, then tapered).
- Both groups received intensive insulin therapy (continuous subcutaneous insulin infusion followed by injections) and were followed for 1 year.
Main Results:
- The prednisone group (Group 1) required significantly more insulin at 30 and 60 days compared to the control group (Group 2).
- Both groups achieved similar stable HbA1c levels around 3 months.
- Fasting C-peptide levels peaked earlier in Group 1 (90 days) than in Group 2 (60 days), but partial remission rates were comparable by 180 days.
Conclusions:
- Short-term prednisone treatment did not reduce insulin requirements or enhance partial remission rates in children with new-onset T1DM.
- While prednisone transiently increased C-peptide levels, it did not provide sustained benefits for beta-cell preservation or metabolic control.
- These findings suggest that short-term immunosuppression with prednisone is not beneficial for managing pediatric T1DM.
Abstract:
Thirty-one children suffering from type I diabetes mellitus were arranged at onset of the disease in two different groups. Group 1 was treated with oral prednisone (60 mg X m-2 X day-1 for 14 days, 30 and 15 mg X m-2 X day-1 for 7 days). Group 2 matched the control group. All patients were treated with continuous subcutaneous insulin infusion for the first 15 days of treatment, and then with two daily injections of a mixture of intermediate- and fast-acting insulin. All subjects were followed for 1 yr. Group 1 required more insulin than group 2 after 30 days (1.5 +/- 0.3 vs. 0.6 $ 0.2 U X kg-1 X day-1, P less than .001) and after 60 days (0.8 +/- 0.1 vs. 0.5 +/- 0.06 U X kg-1 X day-1, P less than .001). After 3 mo, both groups reached the lowest mean stable HbA1 level (8.4 +/- 0.4 and 8.3 +/- 0.4% group 1 and 2 respectively). Between the 2nd and 9th mo of follow-up, mean postbreakfast C-peptide concentration increased in both groups. The highest levels of fasting C-peptide were reached by group 1 after 90 days (0.77 +/- 0.32 nM) and group 2 after 60 days (0.34 +/- 0.09 nM). The largest partial remission (C-peptide 0.3 nM, insulin requirement less than 0.5 U X kg-1 X day-1 and no glycosuria) was observed in group 1 after 180 days (5 of 16 patients) and in group 2 after 60 days (5 of 15 patients).(ABSTRACT TRUNCATED AT 250 WORDS)